Abivax SA
ABVX117.670USD
+6.960+6.29%
終値 02/06, 16:00（ET）15分遅れの株価
0.00時価総額
--直近12ヶ月PER
詳細情報 Abivax SA 企業名
Abivax SA is a clinical stage biopharmaceutical company focusing on the discovery, development and commercialization of anti-viral compounds and therapeutic vaccines against severe and life threatening infectious diseases. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The Company's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.
Abivax SAの企業情報
企業コードABVX
会社名Abivax SA
上場日Jun 26, 2015
最高経営責任者「CEO」de Garidel (Marc)
従業員数- -
証券種類Depository Receipt
決算期末- -
本社所在地7-11 Boulevard Haussmann
都市PARIS
証券取引所NASDAQ OMX - NASDAQ BASIC
国France
郵便番号75009
電話番号33153830963
ウェブサイトhttps://www.abivax.com/
企業コードABVX
上場日Jun 26, 2015
最高経営責任者「CEO」de Garidel (Marc)
Abivax SAの経営陣
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Pierre Courteille
Mr. Pierre Courteille
Chief Business Officer
Chief Business Officer
--
--
Mr. Didier Scherrer, Ph.D.
Mr. Didier Scherrer, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Didier Bruno Blondel
Mr. Didier Bruno Blondel
Chief Financial Officer, Executive Vice President, Non-Member Secretary of the Board of Directors
Chief Financial Officer, Executive Vice President, Non-Member Secretary of the Board of Directors
--
--
Ms. Corinna Zur Bonsen-Thomas
Ms. Corinna Zur Bonsen-Thomas
Independent Director
Independent Director
--
--
Mr. Kinam Hong
Mr. Kinam Hong
Director, Representative of Sofinnova Partners
Director, Representative of Sofinnova Partners
--
--
Mr. Jerome Denis, Ph.D.
Mr. Jerome Denis, Ph.D.
Executive Vice President - Process Development & Manufacturing
Executive Vice President - Process Development & Manufacturing
--
--
Mr. Marc de Garidel
Mr. Marc de Garidel
Chief Executive Officer
Chief Executive Officer
--
--
Ms. Ida Hatoum
Ms. Ida Hatoum
Chief People Officer, Chief Compliance Officer
Chief People Officer, Chief Compliance Officer
--
--
Dr. June H. Lee, M.D.
Dr. June H. Lee, M.D.
Independent Director
Independent Director
--
--
Mr. Troy A. Ignelzi
Mr. Troy A. Ignelzi
Independent Director
Independent Director
--
--
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Pierre Courteille
Mr. Pierre Courteille
Chief Business Officer
Chief Business Officer
--
--
Mr. Didier Scherrer, Ph.D.
Mr. Didier Scherrer, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Didier Bruno Blondel
Mr. Didier Bruno Blondel
Chief Financial Officer, Executive Vice President, Non-Member Secretary of the Board of Directors
Chief Financial Officer, Executive Vice President, Non-Member Secretary of the Board of Directors
--
--
Ms. Corinna Zur Bonsen-Thomas
Ms. Corinna Zur Bonsen-Thomas
Independent Director
Independent Director
--
--
Mr. Kinam Hong
Mr. Kinam Hong
Director, Representative of Sofinnova Partners
Director, Representative of Sofinnova Partners
--
--
Mr. Jerome Denis, Ph.D.
Mr. Jerome Denis, Ph.D.
Executive Vice President - Process Development & Manufacturing
Executive Vice President - Process Development & Manufacturing
--
--
収益内訳
会社から関連データがまだ開示されていません。
会社から関連データがまだ開示されていません。
事業別
地域別
会社から関連データがまだ開示されていません。
株主
更新時刻: Mon, Jan 19
更新時刻: Mon, Jan 19
株主統計
種類
株主統計
株主統計
比率
TCG Crossover Management, LLC
9.67%
UBS Financial Services, Inc.
6.01%
Darwin Global Management Ltd
4.30%
Point72 Asset Management, L.P.
3.98%
Cormorant Asset Management, LP
2.65%
他の
73.39%
株主統計
株主統計
比率
TCG Crossover Management, LLC
9.67%
UBS Financial Services, Inc.
6.01%
Darwin Global Management Ltd
4.30%
Point72 Asset Management, L.P.
3.98%
Cormorant Asset Management, LP
2.65%
他の
73.39%
種類
株主統計
比率
Hedge Fund
33.85%
Investment Advisor
23.60%
Investment Advisor/Hedge Fund
8.93%
Research Firm
2.98%
Venture Capital
2.18%
Private Equity
1.77%
Pension Fund
1.00%
Bank and Trust
0.02%
他の
25.67%
機関投資家保有株
更新時刻: Mon, Dec 8
更新時刻: Mon, Dec 8
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q4
216
53.64M
52.23%
+104.02K
2025Q3
210
53.54M
52.22%
+19.70M
2025Q2
81
30.74M
57.27%
-1.09M
2025Q1
75
31.82M
50.24%
-38.10K
2024Q4
68
29.91M
44.59%
+2.48M
2024Q3
54
27.43M
45.93%
-700.83K
2024Q2
51
33.52M
46.25%
-227.21K
2024Q1
46
28.78M
34.33%
+7.18M
2023Q4
33
27.04M
1.75%
+20.54M
2023Q3
1
5.40M
0.00%
--
詳細を見る
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
TCG Crossover Management, LLC
7.11M
9.67%
+1.05M
+17.42%
Sep 30, 2025
UBS Financial Services, Inc.
4.46M
6.06%
+4.29M
+2560.74%
Sep 30, 2025
Darwin Global Management Ltd
3.16M
4.3%
+3.16M
--
Sep 30, 2025
Point72 Asset Management, L.P.
2.93M
3.98%
+2.76M
+1642.45%
Sep 30, 2025
Cormorant Asset Management, LP
1.95M
2.65%
-180.00K
-8.45%
Sep 30, 2025
Paradigm BioCapital Advisors LP
1.56M
2.13%
+1.56M
--
Sep 30, 2025
Caligan Partners, LP
1.45M
1.97%
-222.48K
-13.29%
Sep 30, 2025
Fidelity Management & Research Company LLC
1.43M
1.94%
+417.90K
+41.26%
Sep 30, 2025
Fred Alger Management, LLC
1.23M
1.67%
+40.31K
+3.38%
Dec 31, 2025
Adar1 Capital Management LLC
1.35M
1.84%
-1.72M
-56.02%
Sep 30, 2025
詳細を見る
関連ETF
更新時刻: Sat, Dec 6
更新時刻: Sat, Dec 6
銘柄名
比率
Simplify Health Care ETF
2.86%
Harbor Health Care ETF
0.7%
Fidelity Nasdaq Composite Index ETF
0.01%
First Trust Multi-Manager Small Cap Opportunities ETF
0%
Innovator IBD Breakout Opportunities ETF
0%
Simplify Health Care ETF
比率2.86%
Harbor Health Care ETF
比率0.7%
Fidelity Nasdaq Composite Index ETF
比率0.01%
First Trust Multi-Manager Small Cap Opportunities ETF
比率0%
Innovator IBD Breakout Opportunities ETF
比率0%
配当金
過去5年間の配当金総支払額は
0.00
米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし
株式分割
日付
配当落ち日
種類
比率
データなし
日付
配当落ち日
種類
比率
データなし
